TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01171508

Intervention type: DEVICE
Intervention: Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA
Description: Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.

Intervention type: DEVICE
Intervention: Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)
Description: Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).

Intervention type: DEVICE
Intervention: Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)
Description: Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.

Intervention type: PROCEDURE
Intervention: Urine 6-sulphatoxymelatonin (aMT6s)
Description: Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.

Intervention type: OTHER
Intervention: Karolinska Sleepiness Scale
Description: Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.

Intervention type: OTHER
Intervention: Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain
Description: Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.

Intervention type: OTHER
Intervention: Sleep-diary
Description: Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
Study: NCT04198506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored tacrolimus dosing
Description: Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tacrolimus dosing
Description: Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
Study: NCT03437057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (below or equal to) 250 mg
Description: Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
Study: NCT03847636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CryoBalloon ablation
Description: Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CryoBalloon ablation
Description: Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
Study: NCT01376882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
Study: NCT01032590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet weight loss intervention
Description: Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet weight loss intervention
Description: Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
Study: NCT00627731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate (mPSL)
Description: mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone (PSL)
Description: PSL 40 mg per day for 10 days
Study: NCT01155531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline plus Telenzepine
Description: oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
Study: NCT00218244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Nicotine Smokeless Tobacco Product
Description: Skoal for 50% reduction;Skoal bandits for 75% reduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Nicotine Smokeless Tobacco Product
Description: Skoal for 50% reduction;Skoal bandits for 75% reduction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Counseling
Description: Behavioral counseling alone for reduction in tobacco use.
Study: NCT01776099

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement (4 arms, 2 active, 2 placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement (4 arms, 2 active, 2 placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement (4 arms, 2 active, 2 placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement (4 arms, 2 active, 2 placebo)
Study: NCT01155531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline plus Telenzepine
Description: oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline plus Telenzepine
Description: oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
Study: NCT02563184

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Study: NCT02196181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT01854567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of one MPC expanded cord unit and one unexpanded cord unit
Description: Infusion of one MPC expanded cord unit and one unexpanded cord unit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of two unexpanded cord blood units.
Description: Umbilical Cord Blood.
Study: NCT02138578

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study: NCT03867474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
Study: NCT03870633

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo medical chart abstraction

Intervention type: OTHER
Intervention: Interview
Description: Complete telephone interview

Intervention type: OTHER
Intervention: Questionnaire
Description: Ancillary studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03078543

Intervention type: DEVICE
Group type: OTHER
Intervention: ANTHEM™ PS Total Knee System implant
Description: The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~* Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~* Titanium primary tibial components~* Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~* Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications.
Study: NCT00001230

Intervention type: DRUG
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine is a drug administered under an IND held by the CDC. Standard dosing is used.
Study: NCT03830151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study: NCT02138578

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Study: NCT04298658

Intervention type: DIAGNOSTIC_TEST
Intervention: Resmed ApneaLink Air device (Resmed, San Diego, CA).
Description: Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).

Intervention type: DIAGNOSTIC_TEST
Intervention: Resmed ApneaLink Air device (Resmed, San Diego, CA).
Description: Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
Study: NCT04590729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-min Exercise Per 30 Min
Description: This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-min Exercise Per 15 Min
Description: This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
Study: NCT03331172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
Study: NCT04298658

Intervention type: OTHER
Intervention: Quantitative Sensory testing (QST)
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.

Intervention type: OTHER
Intervention: Quantitative Sensory testing (QST)
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.

Intervention type: OTHER
Intervention: Quantitative Sensory testing (QST)
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.

Intervention type: OTHER
Intervention: Quantitative Sensory testing (QST)
Description: All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.

Intervention type: DIAGNOSTIC_TEST
Intervention: OraQuick Advance Rapid HIV 1/2 Swab test
Description: Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.

Intervention type: DIAGNOSTIC_TEST
Intervention: OraQuick Advance Rapid HIV 1/2 Swab test
Description: Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cluster of Differentiation 4 (CD4) and Viral load
Description: Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cluster of Differentiation 4 (CD4) and Viral load
Description: Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
Study: NCT04569825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ophtamesone
Description: local application intranasally as drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ophtamesone
Description: local application intranasally as drops
Study: NCT03150641

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord clamping
Description: The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Umbilical cord clamping
Description: The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
Study: NCT02629809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT01628809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: three-day mindfulness-based meditation retreat program
Study: NCT00089128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT02088944

Intervention type: DRUG
Intervention: Infliximab
Study: NCT02232646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
Study: NCT01628809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: three-day mindfulness-based meditation retreat program
Study: NCT03733483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
Study: NCT02955550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-2
Description: Human recombinant Interleukin-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNK-007
Description: PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
Study: NCT00625729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Day 0-14, 10 million international units, 3 times per week for 6 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic natural killer cells
Description: Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
Study: NCT04481009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
Study: NCT00625729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg intravenous (IV) on Day -5.
Study: NCT01765647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGY
Description: AGY is a natural health product produced in egg yolks
Study: NCT03531372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mipolixin®
Description: 1.55g chewable tablet 5 times a day for 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poliprotect®
Description: 1.55 g chewable tablet 5 times a day for 2 weeks
Study: NCT01744899

Intervention type: OTHER
Intervention: Sitting posture
Description: The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.

Intervention type: OTHER
Intervention: Sitting posture
Description: The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
Study: NCT01721369

Intervention type: DIAGNOSTIC_TEST
Intervention: Transient Loss of Consciousness (T-LOC)
Study: NCT01346137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: 15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
Study: NCT04459910

Intervention type: PROCEDURE
Intervention: Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair
Description: After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
Study: NCT03348631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT00695994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and carboplatin
Description: Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.